- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, Placebo
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 31
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 870 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 53
- States / cities
- Birmingham, Alabama • La Jolla, California • Long Beach, California + 50 more
- Conditions
- HCV Infection
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 39
- States / cities
- Beverly Hills, California • La Jolla, California • Los Angeles, California + 34 more
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, RBV, GS-9669
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 101 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Chronic Hepatitis C
- Interventions
- GS-5885, GS-9451, RBV, PEG
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 26
- States / cities
- Los Angeles, California • Sacramento, California • San Diego, California + 20 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 95 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 6
- States / cities
- Boston, Massachusetts • Detroit, Michigan • The Bronx, New York + 3 more
- Conditions
- Hepatitis B
- Interventions
- Ledipasvir 90 MG / Sofosbuvir 400 MG Oral Tablet [Harvoni], Sofosbuvir 400 MG [Sovaldi], Ledipasvir 90 MG
- Drug
- Lead sponsor
- University of Maryland, Baltimore
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2021
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 1
- States / cities
- Lutherville, Maryland
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 13
- States / cities
- Sacramento, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, peginterferon alfa-2a, ribavirin tablet, GS-9451 Placebo
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 351 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 21
- States / cities
- Tucson, Arizona • Beverly Hills, California • Coronado, California + 17 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, VDV, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 47 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- San Antonio, Texas
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Years to 17 Years
- Enrollment
- 226 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Los Angeles, California • San Francisco, California + 20 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Sofosbuvir, Ledipasvir, GS-9669, GS-9451
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 229 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 3
- States / cities
- Washington D.C., District of Columbia • Bethesda, Maryland
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885, GS-9451, tegobuvir, placebo to match tegobuvir, placebo to match RBV, Ribavirin
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 37
- States / cities
- Tucson, Arizona • Anaheim, California • Beverly Hills, California + 30 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 6,625 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 162
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- Not listed
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 570 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2018
- U.S. locations
- 158
- States / cities
- Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more
- Conditions
- Chronic Hepatitis C Virus
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 647 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2014
- U.S. locations
- 52
- States / cities
- Birmingham, Alabama • La Jolla, California • Los Angeles, California + 49 more
- Conditions
- Chronic HCV Infection
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 339 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 30
- States / cities
- Phoenix, Arizona • San Diego, California • San Francisco, California + 25 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 6
- States / cities
- San Francisco, California • Chicago, Illinois • New Orleans, Louisiana + 3 more
- Conditions
- Hepatitis C, Chronic
- Interventions
- GS-5885 tablet, GS-9451 tablet, peginterferon alfa-2a, ribavirin tablet
- Drug · Biological
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 54
- States / cities
- Dothan, Alabama • Montgomery, Alabama • Beverly Hills, California + 43 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- Sofosbuvir (SOF), Ledipasvir/Sofosbuvir (LDV/SOF), Sofosbuvir/Velpatasvir (SOF/VEL), Sofosbuvir/Velpatasvir/Voxilaprevir (SOF/VEL/VOX)
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 461 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2023
- U.S. locations
- 27
- States / cities
- Phoenix, Arizona • Los Angeles, California • San Francisco, California + 24 more
- Conditions
- Hepatitis C Virus Infection
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 87 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 38
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Pasadena, California + 31 more
- Conditions
- Hepatitis C Virus, HIV
- Interventions
- LDV/SOF, RBV
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 335 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 34
- States / cities
- Birmingham, Alabama • Los Angeles, California • Newport Beach, California + 31 more
- Conditions
- HIV-1 Infection, HCV Infection
- Interventions
- E/C/F/TAF, F/R/TAF, LDV/SOF
- Drug
- Lead sponsor
- Gilead Sciences
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 42
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Los Angeles, California + 32 more